Skip to main content
. 2023 Feb 9;66(4):2663–2680. doi: 10.1021/acs.jmedchem.2c01627

Scheme 2. Synthesis of Alkyne Derivatives of the Investigational COVID-19 Therapeutics GC376 (3) and MI-09 (4).

Scheme 2

Reagents and conditions: (a) 16(27) or 17, COMU,55 NMM, DMF/CH2Cl2, 0 °C to rt, 14 and 13%, respectively; (b) COMU,55 NMM, DMF/CH2Cl2, 0 °C to rt, 33%.